Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy

Results from the aichi hypertrophic cardiomyopathy (AHC) registry

Masataka Yoshinaga, Daiji Yoshikawa, Hideki Ishii, Akihiro Hirashiki, Takahiro Okumura, Aki Kubota, Shinichi Sakai, Ken Harada, Fuji Somura, Tomofumi Mizuno, Wakaya Fujiwara, Hiroatsu Yokoi, Mutsuharu Hayashi, Junichi Ishii, Yukio Ozaki, Toyoaki Murohara, Yukihiko Yoshida, Tetsuya Amano, Hideo Izawa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM) has various morphological and clinical features. A decade has passed since the previous survey of the epidemiological and clinical characteristics of Japanese HCM patients. The Aichi Hypertrophic Cardiomyopathy (AHC) Registry is based on a prospective multicenter observational study of HCM patients. The clinical characteristics of 42 ambulant HCM patients followed up for up to 5 years were investigated. The primary endpoint was major adverse cardiac events (MACE), defined as death, non-fatal stroke, admission due to congestive heart failure (CHF), or episodes of sustained ventricular tachycardia/fibrillation. The MACE-free survival during the 5-year follow-up period was 76% according to Kaplan–Meier analysis. HCM-related death occurred in 3 (7%) patients and SCD occurred in 2 (5%) patients. Additionally, 3 (7%) patients were admitted to the hospital due to CHF. Meanwhile, sustained VT was detected in one (2%) of the patients who received ICD implantation and subsequently terminated with antitachycardia pacing using an ICD. The patients with HCM exhibiting left ventricular outflow obstruction (HOCM) had a slightly lower MACE-free survival rate than those with neither HOCM nor dilated-HCM (dHCM) (71% versus 81%, log-rank P = 0.581). Furthermore, the patients with dHCM demonstrated a significantly lower MACE-free survival rate than those with neither HOCM nor dHCM (33% versus 81%, log-rank P = 0.029). In the AHC Registry targeting current Japanese HCM patients, we demonstrated that many HCM patients continue to suffer from MACE despite the development of various treatments for HCM.

Original languageEnglish
Pages (from-to)415-420
Number of pages6
JournalInternational heart journal
Volume56
Issue number4
DOIs
Publication statusPublished - 13-07-2015

Fingerprint

Hypertrophic Cardiomyopathy
Registries
Disease-Free Survival
Survival Rate
Heart Failure
Ventricular Outflow Obstruction
Dilated Cardiomyopathy
Ventricular Fibrillation
Ventricular Tachycardia
Multicenter Studies
Observational Studies
Stroke

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Yoshinaga, Masataka ; Yoshikawa, Daiji ; Ishii, Hideki ; Hirashiki, Akihiro ; Okumura, Takahiro ; Kubota, Aki ; Sakai, Shinichi ; Harada, Ken ; Somura, Fuji ; Mizuno, Tomofumi ; Fujiwara, Wakaya ; Yokoi, Hiroatsu ; Hayashi, Mutsuharu ; Ishii, Junichi ; Ozaki, Yukio ; Murohara, Toyoaki ; Yoshida, Yukihiko ; Amano, Tetsuya ; Izawa, Hideo. / Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy : Results from the aichi hypertrophic cardiomyopathy (AHC) registry. In: International heart journal. 2015 ; Vol. 56, No. 4. pp. 415-420.
@article{f75869b0818744bd9534081433584a46,
title = "Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy: Results from the aichi hypertrophic cardiomyopathy (AHC) registry",
abstract = "Hypertrophic cardiomyopathy (HCM) has various morphological and clinical features. A decade has passed since the previous survey of the epidemiological and clinical characteristics of Japanese HCM patients. The Aichi Hypertrophic Cardiomyopathy (AHC) Registry is based on a prospective multicenter observational study of HCM patients. The clinical characteristics of 42 ambulant HCM patients followed up for up to 5 years were investigated. The primary endpoint was major adverse cardiac events (MACE), defined as death, non-fatal stroke, admission due to congestive heart failure (CHF), or episodes of sustained ventricular tachycardia/fibrillation. The MACE-free survival during the 5-year follow-up period was 76{\%} according to Kaplan–Meier analysis. HCM-related death occurred in 3 (7{\%}) patients and SCD occurred in 2 (5{\%}) patients. Additionally, 3 (7{\%}) patients were admitted to the hospital due to CHF. Meanwhile, sustained VT was detected in one (2{\%}) of the patients who received ICD implantation and subsequently terminated with antitachycardia pacing using an ICD. The patients with HCM exhibiting left ventricular outflow obstruction (HOCM) had a slightly lower MACE-free survival rate than those with neither HOCM nor dilated-HCM (dHCM) (71{\%} versus 81{\%}, log-rank P = 0.581). Furthermore, the patients with dHCM demonstrated a significantly lower MACE-free survival rate than those with neither HOCM nor dHCM (33{\%} versus 81{\%}, log-rank P = 0.029). In the AHC Registry targeting current Japanese HCM patients, we demonstrated that many HCM patients continue to suffer from MACE despite the development of various treatments for HCM.",
author = "Masataka Yoshinaga and Daiji Yoshikawa and Hideki Ishii and Akihiro Hirashiki and Takahiro Okumura and Aki Kubota and Shinichi Sakai and Ken Harada and Fuji Somura and Tomofumi Mizuno and Wakaya Fujiwara and Hiroatsu Yokoi and Mutsuharu Hayashi and Junichi Ishii and Yukio Ozaki and Toyoaki Murohara and Yukihiko Yoshida and Tetsuya Amano and Hideo Izawa",
year = "2015",
month = "7",
day = "13",
doi = "10.1536/ihj.14-418",
language = "English",
volume = "56",
pages = "415--420",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "4",

}

Yoshinaga, M, Yoshikawa, D, Ishii, H, Hirashiki, A, Okumura, T, Kubota, A, Sakai, S, Harada, K, Somura, F, Mizuno, T, Fujiwara, W, Yokoi, H, Hayashi, M, Ishii, J, Ozaki, Y, Murohara, T, Yoshida, Y, Amano, T & Izawa, H 2015, 'Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy: Results from the aichi hypertrophic cardiomyopathy (AHC) registry', International heart journal, vol. 56, no. 4, pp. 415-420. https://doi.org/10.1536/ihj.14-418

Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy : Results from the aichi hypertrophic cardiomyopathy (AHC) registry. / Yoshinaga, Masataka; Yoshikawa, Daiji; Ishii, Hideki; Hirashiki, Akihiro; Okumura, Takahiro; Kubota, Aki; Sakai, Shinichi; Harada, Ken; Somura, Fuji; Mizuno, Tomofumi; Fujiwara, Wakaya; Yokoi, Hiroatsu; Hayashi, Mutsuharu; Ishii, Junichi; Ozaki, Yukio; Murohara, Toyoaki; Yoshida, Yukihiko; Amano, Tetsuya; Izawa, Hideo.

In: International heart journal, Vol. 56, No. 4, 13.07.2015, p. 415-420.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical characteristics and long-term outcomes of hypertrophic cardiomyopathy

T2 - Results from the aichi hypertrophic cardiomyopathy (AHC) registry

AU - Yoshinaga, Masataka

AU - Yoshikawa, Daiji

AU - Ishii, Hideki

AU - Hirashiki, Akihiro

AU - Okumura, Takahiro

AU - Kubota, Aki

AU - Sakai, Shinichi

AU - Harada, Ken

AU - Somura, Fuji

AU - Mizuno, Tomofumi

AU - Fujiwara, Wakaya

AU - Yokoi, Hiroatsu

AU - Hayashi, Mutsuharu

AU - Ishii, Junichi

AU - Ozaki, Yukio

AU - Murohara, Toyoaki

AU - Yoshida, Yukihiko

AU - Amano, Tetsuya

AU - Izawa, Hideo

PY - 2015/7/13

Y1 - 2015/7/13

N2 - Hypertrophic cardiomyopathy (HCM) has various morphological and clinical features. A decade has passed since the previous survey of the epidemiological and clinical characteristics of Japanese HCM patients. The Aichi Hypertrophic Cardiomyopathy (AHC) Registry is based on a prospective multicenter observational study of HCM patients. The clinical characteristics of 42 ambulant HCM patients followed up for up to 5 years were investigated. The primary endpoint was major adverse cardiac events (MACE), defined as death, non-fatal stroke, admission due to congestive heart failure (CHF), or episodes of sustained ventricular tachycardia/fibrillation. The MACE-free survival during the 5-year follow-up period was 76% according to Kaplan–Meier analysis. HCM-related death occurred in 3 (7%) patients and SCD occurred in 2 (5%) patients. Additionally, 3 (7%) patients were admitted to the hospital due to CHF. Meanwhile, sustained VT was detected in one (2%) of the patients who received ICD implantation and subsequently terminated with antitachycardia pacing using an ICD. The patients with HCM exhibiting left ventricular outflow obstruction (HOCM) had a slightly lower MACE-free survival rate than those with neither HOCM nor dilated-HCM (dHCM) (71% versus 81%, log-rank P = 0.581). Furthermore, the patients with dHCM demonstrated a significantly lower MACE-free survival rate than those with neither HOCM nor dHCM (33% versus 81%, log-rank P = 0.029). In the AHC Registry targeting current Japanese HCM patients, we demonstrated that many HCM patients continue to suffer from MACE despite the development of various treatments for HCM.

AB - Hypertrophic cardiomyopathy (HCM) has various morphological and clinical features. A decade has passed since the previous survey of the epidemiological and clinical characteristics of Japanese HCM patients. The Aichi Hypertrophic Cardiomyopathy (AHC) Registry is based on a prospective multicenter observational study of HCM patients. The clinical characteristics of 42 ambulant HCM patients followed up for up to 5 years were investigated. The primary endpoint was major adverse cardiac events (MACE), defined as death, non-fatal stroke, admission due to congestive heart failure (CHF), or episodes of sustained ventricular tachycardia/fibrillation. The MACE-free survival during the 5-year follow-up period was 76% according to Kaplan–Meier analysis. HCM-related death occurred in 3 (7%) patients and SCD occurred in 2 (5%) patients. Additionally, 3 (7%) patients were admitted to the hospital due to CHF. Meanwhile, sustained VT was detected in one (2%) of the patients who received ICD implantation and subsequently terminated with antitachycardia pacing using an ICD. The patients with HCM exhibiting left ventricular outflow obstruction (HOCM) had a slightly lower MACE-free survival rate than those with neither HOCM nor dilated-HCM (dHCM) (71% versus 81%, log-rank P = 0.581). Furthermore, the patients with dHCM demonstrated a significantly lower MACE-free survival rate than those with neither HOCM nor dHCM (33% versus 81%, log-rank P = 0.029). In the AHC Registry targeting current Japanese HCM patients, we demonstrated that many HCM patients continue to suffer from MACE despite the development of various treatments for HCM.

UR - http://www.scopus.com/inward/record.url?scp=84936990338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936990338&partnerID=8YFLogxK

U2 - 10.1536/ihj.14-418

DO - 10.1536/ihj.14-418

M3 - Article

VL - 56

SP - 415

EP - 420

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

IS - 4

ER -